For most people needing weight loss treatment, starting now with an available medication is the better choice
But robust human clinical evidence specifically for disc herniations is still developing
No, Ozempic is not associated with significant hepatotoxicity and does not undergo extensive liver metabolism
GLP-1 receptor agonists (like semaglutide) reduced major kidney events by 24% and all-cause death by 20% in the FLOW trial, also stopped early for benefit
What Emerging Research Says GLP-1 Medications May Do to Your Bones - The Studies Your Doctor May Not Have Read Yet Quick Answer: Emerging research from 2024-2025 suggests GLP-1 receptor agonist medications may be associated with bone density changes in specific populations, primarily driven by rapid weight loss rather than a confirmed direct drug effect on bone cells
Key Messages Hyperkalemia is common in individuals with CKD and diabetes, and is associated with increased risk for mortality, cardiovascular events, hospitalizations, and intensive care unit admissions
.webp)
